Search Results - "Toulmonde, M."

Refine Results
  1. 1
  2. 2

    A review of PARP inhibitors: from bench to bedside by Underhill, C., Toulmonde, M., Bonnefoi, H.

    Published in Annals of oncology (01-02-2011)
    “…Poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors, with novel and selective mechanisms of action, have moved from the laboratory to the…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort by Italiano, A., Bessede, A., Pulido, M., Bompas, E., Piperno-Neumann, S., Chevreau, C., Penel, N., Bertucci, F., Toulmonde, M., Bellera, C., Guegan, J. P., Rey, C., Sautès-Fridman, C., Bougoüin, A., Cantarel, C., Kind, M., Spalato, M., Dadone-Montaudie, B., Le Loarer, F., Blay, J. Y., Fridman, W. H.

    Published in Nature Medicine (01-06-2022)
    “…Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced soft-tissue sarcomas (STSs). Retrospective analysis suggests that…”
    Get full text
    Journal Article Magazine Article
  5. 5
  6. 6

    Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study by Le Cesne, A., Marec-Berard, P., Blay, J.-Y., Gaspar, N., Bertucci, F., Penel, N., Bompas, E., Cousin, S., Toulmonde, M., Bessede, A., Fridman, W.H., Sautes-Fridman, C., Kind, M., Le Loarer, F., Pulido, M., Italiano, A.

    Published in European journal of cancer (1990) (01-09-2019)
    “…There are some lines of evidence suggesting a potential role of immunotherapy for treating patients with osteosarcomas. This was an open-label, multicentre,…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10

    Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma by Dufresne, A., Lesluyes, T., Ménétrier-Caux, C., Brahmi, M., Darbo, E., Toulmonde, M., Italiano, A., Mir, O., Le Cesne, A., Le Guellec, S., Valentin, T., Chevreau, C., Bonvalot, S., Robin, Y.M., Coindre, J-M, Caux, C., Blay, J.Y., Chibon, F.

    Published in Oncoimmunology (01-01-2020)
    “…Soft tissue sarcomas are a group of rare and aggressive connective tissue neoplasms for which curative therapeutic opportunities are limited in advanced phase…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13

    Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival by Italiano, A., Toulmonde, M., Cioffi, A., Penel, N., Isambert, N., Bompas, E., Duffaud, F., Patrikidou, A., Lortal, B., Le Cesne, A., Blay, J.-Y., Maki, R.G., Schwartz, G.K., Antonescu, C.R., Singer, S., Coindre, J.-M., Bui, B.

    Published in Annals of oncology (01-06-2012)
    “…Data regarding the role of systemic therapy in patients with advanced well-differentiated/dedifferentiated liposarcomas (WDLPS/DDLPS) are limited. From 2000 to…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16
  17. 17

    CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications by Laroche-Clary, A., Lucchesi, C., Rey, C., Verbeke, S., Bourdon, A., Chaire, V., Algéo, M.-P., Cousin, S., Toulmonde, M., Vélasco, V., Shutzman, J., Savina, A., Le Loarer, F., Italiano, A.

    Published in Annals of oncology (01-04-2018)
    “…Inhibition of ChK1 appears as a promising strategy for selectively potentiate the efficacy of chemotherapeutic agents in G1 checkpoint-defective tumor cells…”
    Get full text
    Journal Article
  18. 18

    Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study by Toulmonde, M., Le Cesne, A., Piperno-Neumann, S., Penel, N., Chevreau, C., Duffaud, F., Bellera, C., Italiano, A.

    Published in Annals of oncology (01-07-2015)
    “…Preclinical data have suggested a therapeutic role of JUN pathway activation in dedifferentiated liposarcoma (DDLPS) tumorigenesis. Aplidin® is a drug inducing…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study by Verschoor, A.J., Litière, S., Marréaud, S., Judson, I., Toulmonde, M., Wardelmann, E., van der Graaf, W.T., Le Cesne, A., Gronchi, A., Gelderblom, H.

    Published in European journal of cancer (1990) (01-05-2018)
    “…In patients with advanced soft tissue sarcoma (STS) treated with chemotherapy, WHO performance status, histologic subtype and histologic grade are known…”
    Get full text
    Journal Article